期刊文献+

顺铂与XAV939联合应用对人肺癌细胞A549增殖、迁移能力的影响及机制 被引量:1

Effects of cisplatin combined with XAV939 on proliferation,migration and transcription factor expression in WNT pathway of human lung cancer A549 cells
下载PDF
导出
摘要 目的观察顺铂联合端锚聚合酶抑制剂XAV939对人肺癌细胞增殖和迁移能力的影响,并探讨其机制。方法将体外培养的人肺癌A549细胞分为空白对照组、顺铂组、XAV939组、顺铂+XAV939组,分别用1μmol/L Na Cl、0.002 g/L顺铂、1μmol/L XAV939、0.002 g/L顺铂+1μmol/L XAV939培养。用MTT法观察各组细胞增殖情况并计算细胞增殖抑制率;用细胞划痕实验和Transwell小室实验观察各组细胞迁移能力;用Western blotting法检测各组细胞中的WNT通路转录因子端锚聚合酶、β-连接素蛋白。结果与对照组相比,顺铂组、XAV939组、顺铂+XAV939组细胞增殖抑制率高(P均<0.05),细胞迁移距离短(P均<0.05),穿膜细胞数少(P均<0.05),细胞中端锚聚合酶、β-连接素蛋白相对表达量低(P均<0.05);与顺铂组和XAV939组相比,顺铂+XAV939组细胞增殖抑制率高(P均<0.05),细胞迁移距离短(P均<0.05),穿膜细胞数少(P均<0.05),细胞中端锚聚合酶、β-连接素蛋白相对表达量低(P均<0.05)。结论顺铂联合XAV939可以抑制人肺癌A549的增殖和迁移,且效果强于单用XAV939或顺铂。这可能与二者抑制WNT通路转录因子端锚聚合酶、β-连接素蛋白表达有关。 Objective To observe the effects of cisplatin combined with tankyrase small molecule inhibitor XAV939 on the proliferation and migration of human lung cancer A549 cells and to investigate the mechanism.Methods The hu-man lung cancer A549 cells were divided into the blank control group (treated with 1 μmol/L NaCl),cisplatin group (treated with 0.002 g/L),XAV939 group (treated with 1 μmol/L),and cisplatin+XAV939 group (treated with 0.002 g/L cisplatin+1 μmol/L XAV939).The cell proliferation and proliferation inhibitory rates in each group were assessed by MTT assay.The cell migration ability was detected by Scratch test and Transwell chamber assay.Then,the protein expres-sion of tankyrase andβ-catenin was detected by Western blotting,respectively.Results Compared with the control group, the proliferation inhibitory rates of cells was higher,the cell migration distance was shorter,the number of transmembrane cells was less,and the protein expression ofβ-catenin and tankyrase was lower in the cisplatin group,XAV939 group,and cisplatin+XAV939 group (all P〈0.05).Compared with the cisplatin and XAV939 group,the proliferation inhibitory rate of the cisplatin +XAV939 group was higher,the cell migration distance was shorter,the number of transmembrane cells was less,and the protein expression ofβ-catenin and tankyrase was lower (all P〈0.05 ).Conclusions Cisplatin com-bined with XAV939 may inhibit the proliferation and migration abilities of A549 cells and the combined effect is more pow-erful that of XAV939 or cisplatin alone.This effect may be correlated with the inhibition of β-catenin expression and tankyrase expression.
作者 李翀 韩燕燕 郑旭 吕艳 兰福 赵杰 LI Chong HAN Yanyan ZHENG Xu LYU Yah LAN Fu ZHAO Jie(First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianfin 300000, China)
出处 《山东医药》 CAS 北大核心 2016年第47期1-3,共3页 Shandong Medical Journal
基金 天津市卫生局科技基金资助项目(2014KZ130)
关键词 XAV939 顺铂 肺癌 细胞增殖 细胞迁移 WNT通路 端锚聚合酶 Β-连接素 XAV939 cisplatin lung carcinoma cell proliferation cell migration WNT pathway tankyrase β-catenin
  • 相关文献

参考文献5

二级参考文献42

  • 1[1]Chong L, van-Steensel B, Broccoli D, et al. A human telomeric protein. Science, 1995; 270:1663 - 1667
  • 2[2]Smith S, Giriat I, Schmitt A, et al. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science, 1998; 282: 1484-1487
  • 3[3]de Lange T. Protection of mammalian telomeres. Oncogene, 2002;21: 532 - 540
  • 4[4]Yamada M, Tsuji N, Nakamura M, et al. Down-regulation of TRF1, TRF2 and TIN2 genes is important to maintain telomeric DNA for gastric cancers. Anticancer Res, 2002; 22:3303 - 3307
  • 5[5]Aragona M, De-Divitiis O, La Torre D, et al. Immunohistochemical TRF1 expression in human primary intracranial tumors. Anticancer Res, 2001; 21:2135-2139
  • 6[6]Saito K, Yagihashi A, Nasu S, el al. Gene expression for suppres sors of telomerase activity (telomeric-repeat binding factors ) in breast cancer. Jpn J Cancer Res, 2002; 93:253 - 258
  • 7[7]Yamada K, Yagihashi A, Yamada M, et al. Decreased gene expression for telomeric-repeat binding factors and TIN2 in malignant hematopoietic cells. Anticancer Res, 2002; 22:1315 - 1320
  • 8[8]Matsutani N, Yokozaki H, Tahara E, et al. Expression of telomeric repeat binding factor 1 and 2 and TRF1-interacting nuclear protein 2 in human gastric carcinomas. Int J Oncol, 2001; 19:507-512
  • 9[9]Ohyashiki JH, Ohyashiki K, Iwama H, et al. Clinical implications of telomerase activity levels in acute leukemia. Clin Cancer Res,1997; 3:619-625
  • 10[10]Ohyashiki JH, Sashida G, Tauchi T, et al. Telomeres and telomerase in hematologic neoplasia. Oncogene, 2002; 21:680-687

共引文献14

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部